Cancer Biotherapy and Radiopharmaceuticals最新文献

{"title":"¹⁸F-FDG PET/CT Combined with Serum Tg and BRAF^V600E Mutation for Evaluating Recurrence/Metastasis in RAIR-DTC: Subgroup Analysis and Clinical Decision-Making Value.","authors":"Ji Liqiu, Zhang Wenwen, Hao Shanhu, Wang Zhiguo, Zhang Guoxu","doi":"10.1177/10849785261432078","DOIUrl":"https://doi.org/10.1177/10849785261432078","url":null,"abstract":"<p><strong>Objective: </strong>This study evaluated the clinical diagnostic efficacy of <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography (<sup>18</sup>F-FDG PET/CT) for recurrence and/or metastasis in patients with radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) and analyzed its correlation with serum thyroglobulin (Tg), BRAF<sup>V600E</sup> mutation status, and postoperative clinical risk stratification.</p><p><strong>Method: </strong>A retrospective analysis was conducted on the <sup>18</sup>F-FDG PET/CT images and clinical data of 47 patients with RAIR-DTC. The diagnostic sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated, and the receiver operating characteristic curve was used to determine the optimal cutoff value of Tg. The correlation between maximum standardized uptake value (SUV<sub>max</sub>) and clinical pathological characteristics was analyzed.</p><p><strong>Results: </strong>For <sup>18</sup>F-FDG PET/CT in detecting RAIR-DTC recurrence/metastasis, the diagnostic sensitivity was 94.87%, specificity 64.71%, PPV 92.50%, and NPV 73.33%. Regarding Tg, the optimal cutoff value for predicting RAIR-DTC recurrence/metastasis was 29.6 ng/mL, with an area under the curve of 0.7677. Further subgroup analysis showed that the serum Tg level in the PET/CT-positive group (212.56 ± 102.90 ng/mL) was significantly higher than that in the PET/CT-negative group (86.53 ± 69.67 ng/mL; t = 2.119, <i>p</i> = 0.039). In terms of clinical stage, the PET/CT positivity rate was significantly higher in patients with advanced RAIR-DTC (clinical stage III/IV) than in those with early-stage disease (81.82% versus 57.14%; <i>p</i> = 0.033). Correlation analysis revealed a positive correlation between <sup>18</sup>F-FDG PET/CT- derived SUV<sub>max</sub> and clinical stage (Pearson correlation coefficient, <i>r</i> = 0.361, <i>p</i> = 0.042). Furthermore, the SUV<sub>max</sub> in the BRAF<sup>V600E</sup>-mutant group was significantly higher than that in the BRAF<sup>V600E</sup> wild-type group (7.84 ± 3.50 versus 3.85 ± 1.26; t = -4.219, <i>p</i> = 0.039). In addition, the detection rate of <sup>18</sup>F-FDG PET/CT for RAIR-DTC recurrence/metastasis was significantly superior to that of Iodine-131 (<sup>131</sup>I) single-photon emission computed tomography/computed tomography (SPECT/CT) (88.89% versus 52.78%; Z = 2.652, <i>p</i> = 0.041).</p><p><strong>Conclusions: </strong><sup>18</sup>F-FDG PET/CT exhibits high diagnostic efficacy for RAIR-DTC recurrence/metastasis, with its positivity and SUV<sub>max</sub> significantly correlated with serum Tg, clinical stage, and BRAF<sup>V600E</sup> mutation. Clinically, this supports three key strategies: (1) Prioritize <sup>18</sup>F-FDG PET/CT follow-up for patients with Tg > 29.6 ng/mL, BRAF<sup>V600E</sup> positivity or postoperative high risk; (2) consider treatment escalation for PET/CT-positive patien","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"10849785261432078"},"PeriodicalIF":2.1,"publicationDate":"2026-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147488752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive Review on How Repurposed Drugs Modulate Antitumor Immunity: Harnessing Damage-Associated Molecular Patterns.","authors":"Rahaman Shaik, Maheshwari Sappidi, Deepika Vemula, Alekhya Munjala, Fatima Sarwar Syeda, Shireen Begum, Huda Khan, Kiranmai Mandava","doi":"10.1177/10849785251389355","DOIUrl":"10.1177/10849785251389355","url":null,"abstract":"<p><p>Recent research has significantly altered the understanding of the immunogenic profile of certain processes of cancer cell death, leading to the recognition of a new subclass of apoptosis called \"immunogenic apoptosis.\" This form of cell death, induced by specific chemotherapeutic agents, has been shown to elicit a \"chemotherapy vaccine effect\" <i>in vivo</i>, effectively stimulating an antitumor immune response. At the molecular level, \"a collection of molecules\" known as \"damage-associated molecular patterns (DAMPs)\" have been identified as key contributors to the immunogenicity of various cell death pathways. Intracellular molecules, such as heat-shock proteins, high-mobility group box 1 protein, and calreticulin, act as DAMPs when exposed or secreted in response to specific certain stressors, stimuli, and modes of cell death. These discoveries have fueled ongoing research focused on the identification of novel DAMPs, uncovering new mechanisms of their exposure or secretion and developing therapeutic agents capable of inducing immunogenic cell death (ICD). In addition, there is growing interest in addressing the current challenges and limitations within this emerging paradigm. The authors believe that this integrated strategy-combining DAMPs, ICD, and anticancer therapies-may hold the key to significantly reducing cancer-related mortality in the near future.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"10849785251389355"},"PeriodicalIF":2.1,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145338214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SPINK4 Expression as a Predictive Biomarker for Radiolabeled Immune Modulator Therapy in Advanced Colorectal Cancer.","authors":"Haihua Long, Yongqi Shen, Shuting Li, Hongxiang Kong, Jianqin Liang","doi":"10.1177/10849785251379696","DOIUrl":"10.1177/10849785251379696","url":null,"abstract":"<p><p>Colorectal cancer (CRC) remains a significant factor contributing to the morbidity and mortality rates linked with cancer throughout the world, especially in its stages of progression. Increasingly attractive therapeutic options include immune modulation combined with preoperative chemotherapy and radiation therapy (CRT). Recent studies have revealed that the protein serine peptidase inhibitor Kazal type 4 (SPINK4), which is abundantly expressed in gastrointestinal tract tissues, plays a role in immune evasion and treatment resistance in cancers. This meta-analysis aims to assess the relationship between SPINK4 expression levels and the therapeutic effectiveness of radiolabeled immune modulators in patients with advanced CRC who are undergoing preoperative chemotherapy and radiation treatment. The degree of SPINK4 expression and a lower objective response to radiolabeled immune modulators showed a statistically significant link. Conversely, patients with low SPINK4 expression have more favorable treatment responses and ongoing clinical improvement following CRT. High SpINK4 expression can act as a negative prognostic biomarker for radiolabeled immune control in advanced CRC.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"10849785251379696"},"PeriodicalIF":2.1,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145234322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultrasound-Guided Optimization of Preoperative Chemoradiotherapy Using ¹³¹I SPECT/CT for Enhanced Targeting in Differentiated Thyroid Carcinoma.","authors":"Baogang Shi, Xiaobo Xu, Xiaofeng Xia, Quanyong Wang","doi":"10.1177/10849785251376447","DOIUrl":"10.1177/10849785251376447","url":null,"abstract":"<p><p>To properly target tumors during preoperative chemoradiotherapy, differentiated thyroid carcinoma (DTC) must be careful. This method increases treatment success and decreases recurrence. Ultrasound coupled with SPECT/CT may provide novel localization and dose planning possibilities. Many systems solely use anatomical or functional imaging. This may result in insufficient dosage delivery and wasted radiation exposure to healthy tissues. These issues are addressed by Dual-Modality Imaging-Guided Adaptive Chemoradiotherapy Planning (DMI-ACP). This innovative approach combines real-time ultrasound imaging with 6 Å SPECT/CT imaging for precise tumor delineation and tailored dosimetry. This system enables clinicians to adjust chemoradiotherapy regimens by seamlessly integrating functional iodine absorption data with anatomical characteristics, thereby targeting therapy to cancerous areas. The outcomes of this method for patients with DTC were promising, including better lesion targeting, reduced radiation exposure to healthy tissues, and improved chemotherapeutic dose distribution. In clinical evaluations, the DMI-ACP framework demonstrated a sensitivity of 94% and a specificity of 89% in identifying malignant lesions compared with traditional imaging techniques. Furthermore, the integration of adaptive planning resulted in a 20% improvement in tumor control probability and a 15% reduction in exposure to surrounding healthy tissue, as assessed through dosimetric analysis. 2023075 Nanjing Drum Tower Hospital Group Suqian Hospital/The Affiliated Suqian Hospital of Xuzhou Medical University.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"10849785251376447"},"PeriodicalIF":2.1,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145253808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Boronophenylalanine-Mediated Boron Neutron Capture Therapy Confers Selective Killing of Cervical Cancer by Exploiting DNA Repair Deficiency.","authors":"Lili Zhang, Rui Quan, Hefa Huang, Menglin Wu, Wei Wang, Lu Zhang, Long Gu, Zhongying Dai","doi":"10.1177/10849785261426657","DOIUrl":"https://doi.org/10.1177/10849785261426657","url":null,"abstract":"<p><strong>Objective: </strong>Boron neutron capture therapy (BNCT) is an emerging binary targeted radiotherapy modality. This study evaluates the therapeutic potential of boronophenylalanine (BPA)-mediated BNCT in cervical cancer and to elucidate its underlying molecular mechanisms.</p><p><strong>Methods: </strong>A comprehensive set of <i>in vitro</i> and <i>in vivo</i> approaches was employed using cervical cancer cell lines (HeLa, SiHa) and normal cervical epithelial cells (H8). The experimental techniques included clonogenic assays, flow cytometry, Western blotting, immunohistochemistry, and xenograft mouse models to assess cytotoxicity, boron uptake, DNA damage response, apoptosis, and therapeutic efficacy.</p><p><strong>Results: </strong>Cervical cancer cells exhibited significantly higher L-type amino acid transporter 1 (LAT1) expression compared with normal controls, which correlated with enhanced BPA uptake. BPA-BNCT induced profound, dose-dependent cell death and reversed the conventional radiotherapeutic sensitivity profiles between cancer and normal cells. Notably, BNCT demonstrated selective cytotoxicity across different pathological subtypes of cervical cancer, with enhanced therapeutic efficacy observed in adenocarcinoma-a subtype typically resistant to conventional radiotherapy. Mechanistically, BNCT triggered complex DNA double-strand breaks that overwhelmed cellular repair mechanisms, despite robust activation of both homologous recombination (via RAD51) and nonhomologous end joining (via KU70/80). This irreparable DNA damage resulted in G2/M phase arrest and activation of the mitochondrial apoptosis pathway. In xenograft models, BPA-BNCT achieved significant tumor growth suppression and substantially prolonged survival, while maintaining a wide therapeutic window and showing no evidence of systemic toxicity.</p><p><strong>Conclusions: </strong>BPA-BNCT exerts potent and selective antitumor effects against cervical cancer through a dual mechanism: LAT1-mediated boron delivery ensures tumor specificity, while the resulting high-linear energy transfer radiation induces DNA damage that capitalizes on the inherent limitations of the tumor cells' DNA repair capacity, leading to catastrophic cell death. The therapy demonstrates a distinct advantage in treating adenocarcinoma subtypes, which are typically less responsive to conventional radiotherapy. These findings provide robust preclinical evidence supporting BNCT as a promising therapeutic approach, particularly for radiotherapy-resistant cervical adenocarcinoma.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"10849785261426657"},"PeriodicalIF":2.1,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147437782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A New Chapter in Radiopharmaceutical Science.","authors":"Ekaterina Dadachova","doi":"10.1177/10849785261424097","DOIUrl":"10.1177/10849785261424097","url":null,"abstract":"","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"105"},"PeriodicalIF":2.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146168092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preparation and Preliminary Evaluation of a Novel ⁶⁸Ga-Labeled Linear Peptide PET Probe Targeting Nectin-4.","authors":"Deng Ke Li, Xue Cen Cao, Chao Mu, Zheng Li, Mu Mei Chen","doi":"10.1177/10849785251393840","DOIUrl":"10.1177/10849785251393840","url":null,"abstract":"<p><strong>Objectives: </strong>Nectin-4 has been successfully used as a target for tumor therapy. Although several bicyclic peptides and antibodies, Nectin-4 positron emission tomography (PET) probes, have been reported for tumor imaging and expression detection, their production costs or pharmacokinetics still need further improvement. This study developed a novel linear peptide PET probe for rapid examination of Nectin-4-related tumors.</p><p><strong>Methods: </strong>[⁶⁸Ga]Ga-NOTA-SP was prepared by a one-step chelation reaction, and its quality control was carried out by using radio-high-performance liquid chromatography and thin-layer chromatography. Molecular docking was used to predict the predominant binding of NOTA-SP to Nectin-4. Cell experiments using SW780 cells and PET/computed tomography (CT) imaging, using the SW780 tumor model, were performed to assess the specific binding and targeting ability of [⁶⁸Ga]Ga-NOTA-SP to Nectin-4. Normal BALB/c mice were used to investigate the plasma concentration-time curves.</p><p><strong>Results: </strong>Under optimal labeling conditions, the labeling efficiency of [⁶⁸Ga]Ga-NOTA-SP can reach above 95%, with a molar-specific activity of 2.45 MBq/nmol and high <i>in vitro</i> stability. The high specificity of [⁶⁸Ga]Ga-NOTA-SP to Nectin-4 is demonstrated by molecular docking and cell uptake experiment, showing a binding energy of -5.4 kcal/mol and K_d value of 2.483 nM, which was further confirmed by PET-CT imaging.</p><p><strong>Conclusions: </strong>[⁶⁸Ga]Ga-NOTA-SP using a linear peptide as a vector shows favorable pharmacokinetics and specific targeting ability to Nectin-4, enabling rapid tumor mouse model imaging. It would be a promising PET/CT imaging probe for optimizing Nectin-4-related tumor diagnoses and therapy.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"169-177"},"PeriodicalIF":2.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145453748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Letter:</i> Comment on \"Long Noncoding RNA DLX6-AS1 Promotes the Progression in Cervical Cancer by Targeting miR-16-5p/ARPP19 Axis\".","authors":"Belma Gözde Özdemir, Duygu Alime Almalı","doi":"10.1177/10849785251392781","DOIUrl":"10.1177/10849785251392781","url":null,"abstract":"","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"197"},"PeriodicalIF":2.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145356835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Gastric Anatomical Subdivisions on the Response to Neoadjuvant Chemotherapy in Gastric Cancer.","authors":"Omer Akay, Mert Guler, Husnu Ozan Sevik, Anil Demir, Sener Simsek, Mahmut Emin Cicek, Furkan Turkoglu, Ufuk Oguz Idiz, Cihad Tatar","doi":"10.1177/10849785251389350","DOIUrl":"10.1177/10849785251389350","url":null,"abstract":"<p><strong>Background: </strong>Response to neoadjuvant chemotherapy (NACT) in locally advanced gastric cancer varies. This study compares tumor response to NACT across anatomical locations, considering clinicopathological differences.</p><p><strong>Materials and methods: </strong>This retrospective study included 212 patients with gastric adenocarcinoma who received NACT followed by surgery. Tumors were classified by location (antrum-pylorus, corpus-fundus, cardia). Treatment response was assessed using the Modified Ryan Scoring System (0 = complete, 1 = near complete, 2 = partial, 3 = minimal/none).</p><p><strong>Results: </strong>Tumor locations were antrum-pylorus (30.2%), corpus-fundus (28.3%), and cardia (41.5%). Localization showed no statistically significant differences in response (<i>p</i> = 0.337). However, cardia tumors were more frequent in Groups 3 (40.9%) and 4 (48.1%), which showed poorer pathological responses, whereas antrum (34.6%) and corpus (38.5%) tumors were more common in Group 1, representing patients with a pathological complete response. These findings suggest that cardia tumors may have a lower response to NACT, although definitive conclusions cannot be drawn. In multivariate analysis, only advanced T stage (T3-4) was independently associated with poor tumor regression grade response (odds ratio 14.3, 95% confidence interval 5.4-37.5, <i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>Tumor response to NACT varied by anatomical location, although differences were not statistically significant. Cardia tumors showed a trend toward lower response rates. To the authors' knowledge, this is the first study evaluating gastric anatomical subgroups in this context. While not conclusive, the findings suggest that tumor location may influence treatment strategies, warranting validation in larger studies.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"189-196"},"PeriodicalIF":2.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145369176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanoparticles of Melatonin and Lactoferrin for Improved Drug Delivery and Targeting Tumors in Cancer Treatment.","authors":"Devansh Shah, Sankha Bhattacharya, Bhupendra G Prajapati, Harsh Tiwari","doi":"10.1177/10849785251392733","DOIUrl":"10.1177/10849785251392733","url":null,"abstract":"<p><p>This review assesses the promise of nanoparticles containing melatonin and lactoferrin (ML-Lf-NPs) in treating cancer, concentrating on their capacity to improve drug delivery, pinpoint tumors, and optimize therapeutic efficacy. A thorough examination of recent progress in nanoparticle-oriented drug delivery systems was performed, highlighting the physicochemical characteristics, mechanisms of action, and biological interactions of ML-Lf-NPs. Melatonin nanoparticles demonstrate antioxidant and anti-inflammatory characteristics that enhance tumor targeting and therapeutic results. Lactoferrin nanoparticles show potential anticancer effects by improving cellular absorption and enabling targeted drug release at tumors. Both systems demonstrate considerable promise for enhancing drug bioavailability and minimizing side effects. ML-Lf-NPs signify creative strategies for cancer treatment. Their distinct characteristics allow for precise delivery and improved therapeutic effectiveness, opening doors for future clinical uses in cancer treatment.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"106-134"},"PeriodicalIF":2.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145483521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}